These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 18591776)
1. Effects of serum concentrations of disopyramide and its metabolite mono-N-dealkyldisopyramide on the anticholinergic side effects associated with disopyramide. Tsuchishita Y; Fukumoto K; Kusumoto M; Ueno K Biol Pharm Bull; 2008 Jul; 31(7):1368-70. PubMed ID: 18591776 [TBL] [Abstract][Full Text] [Related]
2. Relationship between the therapeutic effects or side-effects and the serum disopyramide or mono-N-dealkylated disopyramide concentration after repeated oral administration of disopyramide to arrhythmic patients. Masuhara K; Ohno T; Hamaguchi K; Katoh K; Kashiwada K; Takahashi S; Tanaka Y; Someya K; Ogata H Int J Clin Pharmacol Res; 1995; 15(3):103-13. PubMed ID: 8847151 [TBL] [Abstract][Full Text] [Related]
4. Relationship between alpha 1-acid glycoprotein and distribution of disopyramide and mono-N-dealkyldisopyramide in whole blood. Bredesen JE; Kierulf P Br J Clin Pharmacol; 1986 Sep; 22(3):281-6. PubMed ID: 3768240 [TBL] [Abstract][Full Text] [Related]
5. Accumulation of a disopyramide metabolite in renal failure. Inagaki Y; Amano I; Otsu T ASAIO J; 1993; 39(3):M609-13. PubMed ID: 8268610 [TBL] [Abstract][Full Text] [Related]
6. Relationship between alpha 1-acid glycoprotein and plasma binding of disopyramide and mono-N-dealkyldisopyramide. Bredesen JE; Kierulf P Br J Clin Pharmacol; 1984 Nov; 18(5):779-84. PubMed ID: 6508986 [TBL] [Abstract][Full Text] [Related]
7. [Accumulation of a disopyramide metabolite in renal failure]. Otsu T; Ito T; Inagaki Y; Amano I; Masamoto S; Niwa M Nihon Jinzo Gakkai Shi; 1993 Sep; 35(9):1065-71. PubMed ID: 8230817 [TBL] [Abstract][Full Text] [Related]
8. Enantioselective analysis of disopyramide and mono-N-dealkyldisopyramide in plasma and urine by high-performance liquid chromatography on an amylose-derived chiral stationary phase. Bortocan R; Lanchote VL; Cesarino EJ; Bonato PS J Chromatogr B Biomed Sci Appl; 2000 Jul; 744(2):299-306. PubMed ID: 10993518 [TBL] [Abstract][Full Text] [Related]
9. Simultaneous determination of disopyramide and its mono-N-dealkylated metabolite enantiomers in human plasma and urine by enantioselective high-performance liquid chromatography. Takahashi H; Tamura A; Ogata H; Masuhara K J Chromatogr; 1990 Aug; 529(2):347-58. PubMed ID: 2229254 [TBL] [Abstract][Full Text] [Related]
10. Anticholinergic activity in the serum of patients receiving maintenance disopyramide therapy. Iisalo E; Aaltonen L Br J Clin Pharmacol; 1984 Mar; 17(3):325-9. PubMed ID: 6712865 [TBL] [Abstract][Full Text] [Related]
11. A simple method for the simulation of unbound serum disopyramide concentration in patients. Kishino S; Kohri N; Iseki K; Miyazaki K; Nomura A; Yasuda H J Pharmacobiodyn; 1991 Sep; 14(9):493-9. PubMed ID: 1779403 [TBL] [Abstract][Full Text] [Related]
12. Stereoselective biliary elimination of disopyramide and mono-N-desisopropyldisopyramide in humans. le Corre P; Malledant Y; Chevanne F; Sado P; le Verge R Chirality; 1992; 4(2):80-3. PubMed ID: 1616827 [TBL] [Abstract][Full Text] [Related]
13. Plasma concentrations and protein binding of disopyramide and mono-N-dealkyldisopyramide during chronic oral disopyramide therapy. Aitio ML Br J Clin Pharmacol; 1981 Apr; 11(4):369-75. PubMed ID: 7259930 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of disopyramide in the dog. Importance of mono-N-dealkylated metabolite kinetics in assessing pharmacokinetic modeling of the parent drug. Cook CS; Gwilt PR; Kowalski K; Gupta S; Oppermann J; Karim A Drug Metab Dispos; 1990; 18(1):42-9. PubMed ID: 1970776 [TBL] [Abstract][Full Text] [Related]
15. Kinetics and dynamics of disopyramide and its dealkylated metabolite in healthy subjects. Chiang WT; von Bahr C; Calissendorff B; Dahlqvist R; Emilsson H; Magnusson A; Schenck-Gustafsson K Clin Pharmacol Ther; 1985 Jul; 38(1):37-44. PubMed ID: 4006374 [TBL] [Abstract][Full Text] [Related]
16. Simultaneous determination of disopyramide and mono-N-dealkyldisopyramide enantiomers in plasma and urine by use of a chiral cellulose-derivative column. Echizen H; Ochiai K; Kato Y; Chiba K; Ishizaki T Clin Chem; 1990 Jul; 36(7):1300-4. PubMed ID: 2372941 [TBL] [Abstract][Full Text] [Related]
17. Simultaneous determination of disopyramide and mono-N-dealkyldisopyramide enantiomers in human plasma by capillary electrophoresis. Jabor VA; Lanchote VL; Bonato PL Electrophoresis; 2001 Apr; 22(7):1406-12. PubMed ID: 11379964 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of cimetidine and ranitidine on the pharmacokinetics of disopyramide in man. Jou MJ; Huang SC; Kiang FM; Lai MY; Chao PD J Pharm Pharmacol; 1997 Nov; 49(11):1072-5. PubMed ID: 9401940 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and optimum dose of disopyramide in patients with chronic renal failure. Nagura Y; Kuno T; Yanai M; Maejima M; Okada K; Maeda H; Inoue M; Takahashi S; Hatano M Nihon Jinzo Gakkai Shi; 1991 May; 33(5):539-43. PubMed ID: 1895553 [TBL] [Abstract][Full Text] [Related]